Table 3.
Multivariate analysis with the most important confounders
Univariate analysis HR (95% CI) |
p value | Multivariate analysis HR (95% CI) |
p value | |
---|---|---|---|---|
Chronic kidney injury | 1.3 (0.6–2.5) | 0.49 | – | – |
COPD | 0.8 (0.4–1.9) | 0.69 | – | – |
Ejection fraction | 1.0 (0.9–1.1) | 0.84 | – | |
Diabetes | 1.5 (0.7–2.8) | 0.25 | – | – |
PAD | 1.3 (0.6–2.7) | 0.39 | – | – |
Atrial fibrillation | 1.6 (0.8–2.9) | 0.17 | – | – |
MR ≥ moderate | 1.7 (0.9–3.2) | 0.10 | – | – |
TR ≥ moderate | 1.8 (0.9–4.0) | 0.10 | – | – |
sPAP | 1.0 (0.9–1.1) | 0.21 | – | – |
NT-proBNP | 1.0 (1.0–1.0) | 0.28 | – | – |
Logistic EuroSCORE | 1.0 (0.9–1.1) | 0.17 | – | – |
STS Prom | 1.0 (0.8–1.2) | 0.06 | 1.0 (0.9–1.1) | 0.12 |
Aortic regurgitation post-TAVR | 0.7 (0.3–1.3) | 0.27 | – | – |
NYHA IV | 1.8 (0.7–4.7) | 0.20 | – | – |
LAFI at baseline | 2.0 (1.0–3.8) | 0.03 | 2.0 (1.1–3.9) | 0.03 |
Statistically significant differences are given in bold
HR hazard ratio, CI confidence interval, COPD chronic obstructive pulmonary disease, PAD peripheral artery disease, TAVR transcatheter aortic valve replacement, NYHA New York Heart Association, LAFI left atrial function index, NT-proBNP n-terminal pro brain natriuretic peptide, EuroSCORE European System for Cardiac Operative Risk Evaluation, STS-Score the Society Thoracic of Surgeons-Score, MR mitral regurgitation, TR tricuspid regurgitation, sPAP systolic pulmonary artery pressure